[go: up one dir, main page]

MX2018004019A - Formulacion novedosa y metodos de tratamiento. - Google Patents

Formulacion novedosa y metodos de tratamiento.

Info

Publication number
MX2018004019A
MX2018004019A MX2018004019A MX2018004019A MX2018004019A MX 2018004019 A MX2018004019 A MX 2018004019A MX 2018004019 A MX2018004019 A MX 2018004019A MX 2018004019 A MX2018004019 A MX 2018004019A MX 2018004019 A MX2018004019 A MX 2018004019A
Authority
MX
Mexico
Prior art keywords
treatment methods
novel formulation
distal
methods
intestine
Prior art date
Application number
MX2018004019A
Other languages
English (en)
Other versions
MX389158B (es
Inventor
Florin Timothy
Popat Amirali
Jambhrunkar Siddharth
Original Assignee
ProdrugXtend Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2015903951A external-priority patent/AU2015903951A0/en
Application filed by ProdrugXtend Pty Ltd filed Critical ProdrugXtend Pty Ltd
Publication of MX2018004019A publication Critical patent/MX2018004019A/es
Publication of MX389158B publication Critical patent/MX389158B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invención se relaciona con composiciones farmacéuticas que comprenden 6-tioguanidina (6-TG) en donde la composición está formulada para la liberación de 6-TG en el intestino distal. Métodos para tratar una enfermedad o padecimiento del íleon distal que responden a 6-TG en donde la 6-TG se libera en el intestino distal también se divulgan.
MX2018004019A 2015-09-29 2016-09-29 Formulación novedosa y métodos de tratamiento. MX389158B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2015903951A AU2015903951A0 (en) 2015-09-29 Novel formulation and treatment methods
AU2016901896A AU2016901896A0 (en) 2016-05-20 Novel formulation and treatment methods
PCT/AU2016/050910 WO2017054042A1 (en) 2015-09-29 2016-09-29 Novel formulation and treatment methods

Publications (2)

Publication Number Publication Date
MX2018004019A true MX2018004019A (es) 2018-09-06
MX389158B MX389158B (es) 2025-03-20

Family

ID=58422496

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018004019A MX389158B (es) 2015-09-29 2016-09-29 Formulación novedosa y métodos de tratamiento.

Country Status (9)

Country Link
US (3) US11077112B2 (es)
EP (1) EP3359158A4 (es)
CN (1) CN108289894A (es)
AU (1) AU2016333150B2 (es)
BR (1) BR112018006279A2 (es)
CA (1) CA3038602C (es)
MX (1) MX389158B (es)
WO (1) WO2017054042A1 (es)
ZA (1) ZA201802201B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023182895A1 (en) * 2022-03-25 2023-09-28 Douglas Pharmaceuticals Ltd Improved thiopurine formulation and treatment methods

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8812490D0 (en) 1988-05-26 1988-06-29 Agricultural & Food Res Delayed release formulations
US5691343A (en) * 1995-03-30 1997-11-25 Mayo Foundation For Medical Education And Research Use of topical azathioprine to treat inflammatory bowel disorders
US6166024A (en) * 1995-03-30 2000-12-26 Mayo Foundation For Medical Education And Research Use of topical azathioprine and thioguanine to treat colorectal adenomas
IL127623A0 (en) 1996-06-19 1999-10-28 Regeneron Pharma Tie-2 receptor ligands (tie ligand-3; tie ligand-4) and their uses
DE19732903A1 (de) 1997-07-30 1999-02-04 Falk Pharma Gmbh Pellet-Formulierung zur Behandlung des Intestinaltraktes
US6395273B1 (en) * 1998-06-10 2002-05-28 Promega Corporation Prevention and treatment of inflammatory bowel disease
DE10058772A1 (de) * 2000-11-27 2002-06-06 Falk Pharma Gmbh Verfahren zur Herstellung leicht löslicher Arzneimittelformulierungen und entsprechende Formulierungen
US8188067B2 (en) 2004-04-01 2012-05-29 Teva Pharmaceutical Industries Ltd. Formulations of 6-mercaptopurine
EP1845948A2 (en) 2005-02-09 2007-10-24 DA Volterra Colonic delivery of active agents
EP2098236A1 (en) * 2008-03-03 2009-09-09 Medizinische Hochschule Hannover Cytostatic compositions
WO2009128955A1 (en) * 2008-04-18 2009-10-22 Teva Pharmaceutical Industries Ltd. Treatment of inflammatory bowel disease with 6-mercaptopurine
ES2608050T3 (es) * 2008-12-03 2017-04-05 Synergy Pharmaceuticals Inc. Formulaciones de agonistas de guanilato ciclasa C y métodos de uso
US20130005749A1 (en) * 2011-06-10 2013-01-03 The University Of Queensland Novel formulation and treatment methods
GB2494439A (en) * 2011-09-09 2013-03-13 Nova Bio Pharma Technologies Ltd 6-Mercaptopurine oral suspension for the treatment of acute lymphoblastic leukaemia
EP3362053A4 (en) * 2015-10-16 2019-04-17 Hadasit Medical Research Services and Development Ltd. TREATMENT OF NON-ALCOHOLIC FATTYLENE OR NON-ALCOHOLIC STEATOHEPATITIS WITH 6-MERCAPTOPURIN WITH DELAYED RELEASE

Also Published As

Publication number Publication date
US20240423989A1 (en) 2024-12-26
US11077112B2 (en) 2021-08-03
EP3359158A1 (en) 2018-08-15
WO2017054042A1 (en) 2017-04-06
ZA201802201B (en) 2021-07-28
MX389158B (es) 2025-03-20
CA3038602A1 (en) 2017-04-06
US12109214B2 (en) 2024-10-08
AU2016333150B2 (en) 2021-12-16
US20210393638A1 (en) 2021-12-23
BR112018006279A2 (pt) 2018-10-16
AU2016333150A1 (en) 2018-03-29
CN108289894A (zh) 2018-07-17
CA3038602C (en) 2023-12-05
US20180235972A1 (en) 2018-08-23
EP3359158A4 (en) 2019-05-08

Similar Documents

Publication Publication Date Title
CO2017013443A2 (es) Composiciones que comprenden cepas bacterianas del género blautia
CO2017013446A2 (es) Composiciones que comprenden cepas bacterianas del género bacteroides
AR106768A1 (es) Composiciones que comprenden cepas bacterianas
CL2018000150A1 (es) Compuestos útiles como inmunomoduladores (divisional de solicitud 201600508)
CL2017003151A1 (es) Formulaciones para vacunas contra la neoplasia y métodos para preparar las mismas
CL2018001367A1 (es) Composiciones que comprenden cepas bacterianas
BR112018003212A2 (pt) diacereína ou seus análogos para inibir a expressão de asc, expressão de nlrp3 e / ou formação de complexo inflamassoma nlrp3
MX2016011810A (es) Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso.
MX2016009625A (es) Proteinas quimericas tipo fosfatasa alcalina.
MX2019014122A (es) Formulaciones de dosis fija.
EP3649157A4 (en) COMPOSITIONS AND METHODS OF TREATMENT OR PREVENTION OF DISEASES RELATED TO ENDOCRINE FGF
BR112018007958A2 (pt) composições e métodos que usam um polifenol para a saúde musculoesquelética
MX2016011667A (es) Composiciones topicas que comprenden un extracto de coriolus versicolor para aumentar la autoinmunidad.
MA43314A (fr) Vecteurs de grippe atténues utilisés pour la prophylaxie et/ou le traitement de maladies infectieuses ainsi que pour le traitement de maladies oncologiques
MX2016013236A (es) Formulacion inmunosupresora.
CL2019001053A1 (es) Formulaciones farmacéuticas y métodos para prepararlas.
BR112016024621A2 (pt) composições para tratamento bucal
CL2019000625A1 (es) Combinación de agonistas de fxr.
MX387731B (es) Composiciones farmacéuticas orales de mesalazina.
BR112017009510A2 (pt) composições compreendendo ciclosporina
CL2017000178A1 (es) Compuestos para usar en el tratamiento antihelmíntico
CL2018000430A1 (es) Compuesto de hidroxitriazina y uso médico relacionado.
MX2017003469A (es) Inhibidores macrociclicos de cinasa rip2.
CL2017000884A1 (es) Composición farmacéutica para usarse en el tratamiento o la prevención de deficiencias de vitaminas y minerales en pacientes que han sido sometidos a cirugía de derivación gástrica
CL2017000560A1 (es) Fórmula que incluye glicopirrolato, método y sistema